Please login to the form below

Erivedge

This page shows the latest Erivedge news and features for those working in and with pharma, biotech and healthcare.

Pfizer gets first FDA nod for hedgehog inhibitor in AML

The small-molecule drug blocks part of the Sonic hedgehog pathway, which is also targeted by other cancer drugs including Roche’s Erivedge (vismodegib) and Novartis’ Odomzo (sonidegib) for basal cell ... Erivedge has been discontinued for AML and

Latest news

NICE backs Pfizer’s Xeljanz for RA

Roche’s Erivedge (vismodegib) - which was made available via the old CDF in 2013 - is also set to be cut from the scheme, but patients who are currently receiving the drug
Pfizer's SMO inhibitor boosts survival in blood cancer trial

There are already two SMO (smoothened) inhibitors on the market - Novartis' Odomzo (sonidegib) and Roche's Erivedge (vismodegib) - and both are approved to treat a form of skin cancer known as ... Sales of Erivedge were around $150m in the first nine
EU green light for Novartis' skin cancer therapy

It will compete in the marketplace against Roche's Erivedge (vismodegib), another SMO inhibitor that has been on the market since 2012 and achieved sales of 72m Swiss francs ($75m) in ... Neither drug is expected to be a big seller thanks to the small
FDA approves four new medicines across multiple areas

The pill will compete against Roche's Erivedge (vismodegib), which was the first oral drug for BCC to see approval in 2012, although neither medicine is expected to be a blockbuster
Novartis skin cancer drug clears pivotal trial

This pathway is also targeted by Roche's Erivedge (vismodegib), which was granted approval as a BCC therapy in the US in 2012 and in Europe last year. ... Erivedge sales rocketed more than 160 per cent to reach 75m Swiss francs ($84m) last year has been

More from news
Approximately 3 fully matching, plus 7 partially matching documents found.

Latest Intelligence

Drug launches to watch in 2019

The small-molecule drug blocks part of the Sonic hedgehog pathway, which is also targeted by other cancer drugs including Roche’s Erivedge (vismodegib) and Novartis’ Odomzo (sonidegib) for basal cell

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

Chris Bowden joins Agios

During this time he worked on major cancer medicines, such as melanoma drug Zelboraf (vemurafenib) and Erivedge (vismodegib) for patients with unresectable, locally advanced or metastatic basal cell carcinoma.
Curis looks to MedImmune and Takeda for new hires

Curis also worked with Roche to Erivedge (vismodegib), which recently won approval for the treatment of advanced basal cell carcinoma (BCC).

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Account Manager– Medical Communications: (Negotiable - depending on experience)

Director of Scientific Services, Medical Communications, Six fig...: Six figure salary

Senior Medical Writer, MedComms Agency: Salary TBC

Consultant: competitive salary

Principal Medical Writer: £48 - 58, 000 according to skills and experience benefits

Account Director or Senior Account Director: Salary TBC

Vice President: Competitive Salary Offered

Subscribe to our email news alerts

PMHub

Add my company

Star

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

How do companies prepare for reimbursement?: Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
Integrating electronic health records into clinical trials: How organisations are working to realise the research potential of EHRs...
Keeping up the fight against HIV and using the lessons to tackle other threats: Danny Buckland interviews Gilead’s Mike Elliott...